Compare AISPW & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISPW | AGMB |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | Belgium |
| Employees | 56 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 677.9M |
| IPO Year | N/A | N/A |
| Metric | AISPW | AGMB |
|---|---|---|
| Price | $0.92 | $13.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 17.9K | ★ 106.6K |
| Earning Date | 04-02-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,724,085.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $13.20 |
| 52 Week High | $3.24 | $17.45 |
| Indicator | AISPW | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 40.98 |
| Support Level | $0.74 | $13.43 |
| Resistance Level | $1.14 | $16.16 |
| Average True Range (ATR) | 0.11 | 1.21 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 9.30 | 20.22 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.